Description Results NMA

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

all causes death 1.08 [0.85; 1.37]

CVdeath 1.15 [0.88; 1.51]

CV events 0.96 [0.83; 1.11]

aleglitazar 150 ìg (n=1999)

vs.

placebo (n=0)

double-blind

Parallel groups

Sample size: 1999/0

Primary endpoint: Cv events

FU duration: 58 days

aleglitazar 150 ìg daily (n=3616)

vs.

placebo (n=3610)

double-blind

Parallel groups

Sample size: 3616/3610

Primary endpoint: cardiovascular

FU duration: 2 years ( median)